Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 152
Filter
1.
Gene Ther ; 22(5): 391-403, 2015 May.
Article in English | MEDLINE | ID: mdl-25652098

ABSTRACT

Cancer therapy with T cells expressing chimeric antigen receptors (CARs) has produced remarkable clinical responses in recent trials, but also severe side effects. Whereas most protocols use permanently reprogrammed T cells, we have developed a platform for transient CAR expression by mRNA electroporation. This approach may be useful for safe clinical testing of novel receptors, or when a temporary treatment period is desirable. Herein, we investigated therapy with transiently redirected T cells in vitro and in a xenograft mouse model. We constructed a series of CD19-specific CARs with different spacers and co-stimulatory domains (CD28, OX40 or CD28-OX40). The CAR constructs all conferred T cells with potent CD19-specific activity in vitro. Unexpectedly, the constructs incorporating a commonly used IgG1-CH2CH3 spacer showed lack of anti-leukemia activity in vivo and induced severe, partly CD19-independent toxicity. By contrast, identical CAR constructs without the CH2-domain eradicated leukemia in vivo, without notable toxicity. Follow-up studies demonstrated that the CH2CH3-spacer bound soluble mouse Fcγ-receptor I and mediated off-target T-cell activation towards murine macrophages. Our findings highlight the importance of non-signalling CAR elements and of in vivo studies. Finally, the results show that transiently redirected T cells control leukemia in mice and support the rationale for developing an mRNA-CAR platform.


Subject(s)
Leukemia/therapy , Receptors, Antigen, T-Cell/genetics , Receptors, IgG/genetics , T-Lymphocytes/immunology , Animals , Antigens, CD19/genetics , Antigens, CD19/immunology , CD28 Antigens/genetics , CD28 Antigens/immunology , Cell Line, Tumor , Cells, Cultured , Genetic Therapy , HEK293 Cells , Humans , Immunotherapy, Adoptive , Macrophage Activation , Macrophages/immunology , Mice , Mice, Inbred NOD , Receptors, Antigen, T-Cell/immunology , Receptors, IgG/immunology , Receptors, OX40/genetics , Receptors, OX40/immunology , Recombinant Proteins/genetics , Recombinant Proteins/immunology , T-Lymphocytes/transplantation , Xenograft Model Antitumor Assays
2.
Colloids Surf B Biointerfaces ; 90: 211-6, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-22078925

ABSTRACT

The aim of this work was to encapsulate the CdTe quantum dots within the nanocapsules that were prepared by the layer-by-layer adsorption of polyelectrolytes. Two different polyelectrolyte pairs were used as components of the shell: synthetic polycation poly(allyamine hydrochloride) (PAH), together with anionic poly(sodium styrene sulfonate) (PSS), and biocompatible cationic poly-L-lysine hydrobromide in a pair with biocompatible anionic poly-D-glutamic acid sodium salt (PGA). The saturation method was used for formation of consecutive layers on the initial CdTe-polyelectrolyte complex. A growth of the polyelectrolyte shell was followed with the electrophoretic mobility and light scattering measurements, in order to determine the zeta potential and the size of capsules, respectively. The fluorescent spectra of the quantum dots, which are embedded within the capsules, were characterized with spectrofluorimeter. Later on, they were deposited on a negatively charged mica surface and studied by the means of atomic force microscopy (AFM). In order to estimate the cytotoxicity of capsules, their influence on the B-lymphoblastoid cell line proliferation and on unspecific binding to the P-blood mononuclear cells was examined using the flow cytometry.


Subject(s)
Biocompatible Materials/metabolism , Cell Survival/drug effects , Delayed-Action Preparations/metabolism , Drug Carriers/metabolism , Drug Compounding/methods , Nanocapsules/chemistry , Nanomedicine/methods , Adsorption , Biocompatible Materials/chemistry , Delayed-Action Preparations/chemistry , Drug Carriers/chemistry , Electrolytes , Flow Cytometry , Humans , Microscopy, Atomic Force , Nanocapsules/toxicity , Nanocapsules/ultrastructure , Polyamines/chemistry , Polyelectrolytes , Polymers/chemistry , Quantum Dots , Spectrometry, Fluorescence , Sulfonic Acids/chemistry , Surface Properties , Tumor Cells, Cultured
3.
Scand J Immunol ; 74(6): 632-9, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21883353

ABSTRACT

We evaluated inflammatory markers in febrile neutropenic lymphoma patients undergoing high-dose chemotherapy with autologous stem cell support. Based on MASCC scores, our patients had a low risk of serious complications and a perspective of a benign initial clinical course of the febrile neutropenia. We also studied the impact of tobramycin given once versus three times daily on these immune markers. Sixty-one patients participating in a Norwegian multicentre prospective randomized clinical trial, comparing tobramycin once daily versus three times daily, given with penicillin G to febrile neutropenic patients, constituted a clinically homogenous group. Four patients had bacteraemia, all isolates being Gram-positive. Thirty-two patients received tobramycin once daily, and 29 patients received tobramycin three times daily. Blood samples were taken at the onset of febrile neutropenia and 1-2 days later. All samples were frozen at -70 °C and analysed at the end of the clinical trial for C-reactive protein (CRP), procalcitonin (PCT), complement activation products, mannose-binding lectin (MBL) and 17 cytokines. We found a mild proinflammatory response in this series of patients. CRP was non-specifically elevated. Ten patients with decreased MBL levels showed the same mild clinical and proinflammatory response. Patients receiving tobramycin once daily showed a more pronounced proinflammatory response compared with patients receiving tobramycin three times daily. Overall, febrile neutropenic cancer patients with a benign clinical course show a mild proinflammatory immune response.


Subject(s)
Antineoplastic Agents/adverse effects , Lymphoma , Neutropenia/drug therapy , Tobramycin/therapeutic use , Adolescent , Adult , Aged , Antineoplastic Agents/therapeutic use , Cytokines/immunology , Female , Humans , Inflammation/immunology , Inflammation/microbiology , Lymphoma/drug therapy , Male , Middle Aged , Neutropenia/chemically induced , Risk Factors , Tobramycin/administration & dosage , Tobramycin/adverse effects , Young Adult
4.
Leukemia ; 24(11): 1901-9, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20844564

ABSTRACT

The possibility that allogeneic T cells may be targeted to leukemia has important therapeutic implications. As most tumor antigens represent self-proteins, high-avidity tumor-specific T cells are largely deleted from the repertoire of the patient. In contrast, T cells from major histocompatibility complex (MHC)-mismatched donors provide naïve repertoires wherein such cells have not been systematically eliminated. Yet, evidence for peptide degeneracy or poly-specificity warrants caution in the use of foreign human leukocyte antigen (HLA) or peptide complexes as therapeutic targets. Here, we cocultured HLA-A(*)0201-negative T cells with autologous dendritic cells engineered to present HLA-A(*)0201 complexed with a peptide from the B cell antigen CD20 (CD20p). HLA-A(*)0201/CD20p pentamer-reactive CD8(+) T cells were readily obtained from all donors. The polyclonal cells showed exquisite peptide and MHC specificity, and efficiently killed HLA-A(*)0201-positive B cells, including primary chronic lymphocytic leukemia cells. The T cell receptor (TCR) sequences displayed a novel type of conservation, with extensive homology in the TCR ß chain complementarity-determining region 3 and in J, but not V, region. This is surprising, as the donors were HLA disparate and their TCR repertoires are expected to show little overlap. The results demonstrate the first public recognition motif for an allogeneic HLA/peptide complex. The allo-restricted T cells or TCRs could provide graft-versus-leukemia in the absence of graft-versus-host disease.


Subject(s)
Isoantigens/immunology , Leukemia, B-Cell/immunology , T-Lymphocytes/immunology , Antibody Specificity , Antigens, CD20/immunology , Autoantigens/immunology , B-Lymphocytes/immunology , Dendritic Cells/immunology , Flow Cytometry , HEK293 Cells/immunology , HLA Antigens/immunology , HLA-A Antigens/immunology , HLA-A2 Antigen , Humans , Receptors, Antigen, T-Cell, alpha-beta/immunology
5.
Langmuir ; 26(15): 12592-7, 2010 Aug 03.
Article in English | MEDLINE | ID: mdl-20604580

ABSTRACT

The aim of this work was to develop a novel method of preparation of loaded nanosize capsules based on liquid core encapsulation by biocompatible polyelectrolyte (PE) multilayer adsorption, with or without pegylated outermost layer. Using AOT (docusate sodium salt) as emulsifier, we obtained cores, stabilized by an AOT/PLL (poly-L-lysine hydrobromide) surface complex. These positively charged cores were encapsulated by layer-by-layer adsorption of polyelectrolytes, biocompatible polyanion PGA (poly-L-glutamic acid sodium salt), and biocompatible polycation PLL. We used the saturation method for formation of consecutive layers, and we determined the optimal conditions concerning concentration of surfactant and polyelectrolytes to form stable shells. The average size of the obtained capsules was 60 nm. Pegylated external layer were prepared using PGA-g-PEG (PGA grafted by PEG poly(ethylene glycol)). The capsules were stable for at least a period of 3 months. These nanocapsules were biocompatible when tested for cytotoxicity in a cellular coculture assay and demonstrated no or very low nonspecific binding to peripheral blood mononuclear cells when tested by flow cytometry. In order to study drug effects on leukemia cells, beta-carotene and vitamin A have been encapsulated as model drugs.


Subject(s)
Nanocapsules/chemistry , Polymers/chemistry , Adsorption , Dioctyl Sulfosuccinic Acid/chemistry , Emulsifying Agents/chemistry , Models, Theoretical , Polyamines/chemistry , Polyelectrolytes , Polyglutamic Acid/chemistry
6.
Scand J Immunol ; 69(4): 319-28, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19284496

ABSTRACT

Most tumour-associated antigens (TAA) are non-mutated self-antigens. The peripheral T cell repertoire is devoid of high-avidity TAA-specific cytotoxic T lymphocytes (CTL) due to self-tolerance. As tolerance is major histocompatibility complex-restricted, T cells may be immunized against TAA presented by a non-self human leucocyte antigen (HLA) molecule and transferred to cancer patients expressing that HLA molecule. Obtaining allo-restricted CTL of high-avidity and low cross-reactivity has, however, proven difficult. Here, we show that dendritic cells transfected with mRNA encoding HLA-A*0201, efficiently present externally loaded peptides from the antigen, Melan-A/MART-1 to T cells from HLA-A*0201-negative donors. CD8(+) T cells binding HLA-A*0201/MART-1 pentamers were detected already after 12 days of co-culture in 11/11 donors. The majority of cells from pentamer(+) cell lines were CTL and efficiently killed HLA-A*0201(+) melanoma cells, whilst sparing HLA-A*0201(+) B-cells. Allo-restricted CTL specific for peptides from the leukaemia-associated antigens CD33 and CD19 were obtained with comparable efficiency. Collectively, the results show that dendritic cells engineered to express defined allo-HLA peptide complexes are highly efficient in generating CTL specifically reacting with tumour-associated antigens.


Subject(s)
Antigens, Neoplasm/immunology , Dendritic Cells/immunology , HLA-A Antigens/immunology , Isoantigens/immunology , T-Lymphocytes, Cytotoxic/immunology , Antigen Presentation/immunology , Cell Line, Tumor , Cytotoxicity, Immunologic , Flow Cytometry , HLA-A Antigens/genetics , HLA-A2 Antigen , Humans , Immunotherapy/methods , Lymphocyte Activation/immunology , Peptides/immunology , Polymerase Chain Reaction , Transfection
7.
Eur J Cancer ; 45(8): 1424-31, 2009 May.
Article in English | MEDLINE | ID: mdl-19167214

ABSTRACT

A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult. The development of cancer vaccines is hampered by a range of issues particular to this field of research. On 12th March 2008, the Biotherapy Development Association convened a workshop to discuss issues faced by scientists and clinicians involved in the development of cancer vaccines. This paper is a review of the field, based on discussions held at the BDA workshop, and describes biological barriers encountered in generating effective immune responses to tumours, methodological obstacles encountered in the improvement of immunological monitoring which aims to improve inter-laboratory and inter-trial comparisons, challenges in clinical trial design and problems posed by the lack of specific regulation for cancer vaccines and the impact on their development. Ultimately, a number of general solutions are posed: (1) better patient selection, (2) use of multi-modal treatments that affect several aspects of the immune system at once, (3) a requirement for the development of good biomarkers to stratify patients for selection prior to trial and as surrogates for clinical response and (4) harmonisation of SOPs for immunological monitoring of clinical trials.


Subject(s)
Cancer Vaccines/therapeutic use , Immunotherapy/methods , Neoplasms/therapy , Animals , Drug Resistance, Neoplasm/immunology , Humans , Immunotherapy/trends , Neoplasms/immunology , Patient Selection , Research Design
8.
Cytotherapy ; 9(6): 587-92, 2007.
Article in English | MEDLINE | ID: mdl-17882723

ABSTRACT

BACKGROUND: The use of mRNA in vaccine studies has generally been through loading or transfection of immature DC followed by a maturation step. A recent study has suggested that this strategy may result in inferior priming of cytotoxic T lymphocytes (CTL). Furthermore the study did not address any possible effects on the priming of CD4(+) T-cell responses. METHODS: We compared mRNA transfection of mature DC with that of immature DC, using as a read-out their capacity to prime autologous T cells during one cycle of in vitro stimulation. In this model system we used mRNA from the tumor cell line Jurkat E6. DC transfected at either the immature stage (day 5) or mature stage (day 7) displayed a similar phenotype. RESULTS: Interestingly, no major differences in their ability to prime CD4 and CD8 T-cell responses were observed. As in vitro priming to some extent may reflect the capacity of these DC to prime T cells in vivo after vaccination, these studies support the use of mRNA-transfected mature DC in clinical protocols. DISCUSSION: Transfection of DC at the end of the maturation process represents a logistical improvement in the GMP production of mRNA-transfected DC for clinical protocols.


Subject(s)
Cross-Priming/immunology , Dendritic Cells/metabolism , Electroporation , RNA, Neoplasm/metabolism , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Helper-Inducer/immunology , Transfection , Antigens, Neoplasm/metabolism , Humans , Immunophenotyping , Jurkat Cells , RNA, Messenger
9.
Br J Cancer ; 95(11): 1474-82, 2006 Dec 04.
Article in English | MEDLINE | ID: mdl-17060934

ABSTRACT

Patients with inoperable pancreatic cancer have a dismal prognosis with a mean life expectancy of 3-6 months. New treatment modalities are thus urgently needed. Telomerase is expressed in 85-90% of pancreas cancer, and immunogenic telomerase peptides have been characterised. A phase I/II study was conducted to investigate the safety, tolerability, and immunogenecity of telomerase peptide vaccination. Survival of the patients was also recorded. Forty-eight patients with non-resectable pancreatic cancer received intradermal injections of the telomerase peptide GV1001 at three dose levels, in combination with granulocyte-macrophage colony-stimulating factor. The treatment period was 10 weeks. Monthly booster vaccinations were offered as follow-up treatment. Immune responses were measured as delayed-type hypersensitivity skin reaction and in vitro T-cell proliferation. GV1001 was well tolerated. Immune responses were observed in 24 of 38 evaluable patients, with the highest ratio (75%) in the intermediate dose group. Twenty-seven evaluable patients completed the study. Median survival for the intermediate dose-group was 8.6 months, significantly longer for the low- (P = 0.006) and high-dose groups (P = 0.05). One-year survival for the evaluable patients in the intermediate dose group was 25%. The results demonstrate that GV1001 is immunogenic and safe to use. The survival data indicate that induction of an immune response is correlated with prolonged survival, and the vaccine may offer a new treatment option for pancreatic cancer patients, encouraging further clinical studies.


Subject(s)
Adenocarcinoma/therapy , Cancer Vaccines/administration & dosage , Cancer Vaccines/immunology , Pancreatic Neoplasms/therapy , Peptide Fragments/immunology , Telomerase/immunology , Adenocarcinoma/immunology , Adenocarcinoma/pathology , Adult , Aged , Dose-Response Relationship, Drug , Female , Humans , Hypersensitivity, Delayed/immunology , Male , Middle Aged , Pancreatic Neoplasms/immunology , Pancreatic Neoplasms/pathology , Peptide Fragments/administration & dosage , Recombinant Proteins/immunology , Vaccines, Subunit/immunology , Vaccines, Subunit/therapeutic use , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology
10.
Cancer Gene Ther ; 13(10): 905-18, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16710345

ABSTRACT

We have developed an individualized melanoma vaccine based on transfection of autologous dendritic cells (DCs) with autologous tumor-mRNA. Dendritic cells loaded with complete tumor-mRNA may generate an immune response against a broad repertoire of antigens, including unique patient-specific antigens. The purpose of the present phase I/II trial was to evaluate the feasibility and safety of the vaccine, and the ability of the DCs to elicit T-cell responses in melanoma patients. Further, we compared intradermal (i.d.) and intranodal (i.n.) vaccine administration. Twenty-two patients with advanced malignant melanoma were included, each receiving four weekly vaccines. Monocyte-derived DCs were transfected with tumor-mRNA by electroporation, matured and cryopreserved. We obtained successful vaccine production for all patients elected. No serious adverse effects were observed. A vaccine-specific immune response was demonstrated in 9/19 patients evaluable by T-cell assays (T-cell proliferation/interferon-gamma ELISPOT) and in 8/18 patients evaluable by delayed-type hypersensitivity (DTH) reaction. The response was demonstrated in 7/10 patients vaccinated intradermally and in 3/12 patients vaccinated intranodally. We conclude that immuno-gene-therapy with the described DC-vaccine is feasible and safe, and that the vaccine can elicit in vivo T-cell responses against antigens encoded by the transfected tumor-mRNA. The response rates do not suggest an advantage in applying i.n. vaccination.


Subject(s)
Cancer Vaccines/administration & dosage , Cell Transplantation , Dendritic Cells , Melanoma/therapy , RNA, Messenger/genetics , Transfection , Adult , Aged , Animals , Cancer Vaccines/adverse effects , Dogs , Electroporation , Enzyme-Linked Immunosorbent Assay , Humans , Hypersensitivity, Delayed , Immunity, Cellular , Melanoma/immunology , Middle Aged , T-Lymphocytes/immunology
11.
Br J Cancer ; 93(7): 749-56, 2005 Oct 03.
Article in English | MEDLINE | ID: mdl-16136047

ABSTRACT

Here, we present results from a clinical trial employing a new vaccination method using dendritic cells (DCs) transfected with mRNA from allogeneic prostate cancer cell lines (DU145, LNCaP and PC-3). In all, 20 patients were enrolled and 19 have completed vaccination. Each patient received at least four weekly injections with 2 x 10(7) transfected DCs either intranodally or intradermally. Safety and feasibility of vaccination were determined. Immune responses were measured as delayed-type hypersensitivity and by in vitro immunoassays including ELISPOT and T-cell proliferation in pre- and postvaccination peripheral blood samples. Serum prostate-specific antigen (PSA) levels and bone scans were monitored. No toxicity or serious adverse events related to vaccinations were observed. A total of 12 patients developed a specific immune response to tumour mRNA-transfected DCs. In total, 13 patients showed a decrease in log slope PSA. This effect was strengthened by booster vaccinations. Clinical outcome was significantly related to immune responses (n = 19, P = 0.002, r = 0.68). Vaccination with mRNA-transfected DCs is safe and results in cellular immune responses specific for antigens encoded by mRNA derived from the prostate cancer cell lines. The observation that in some patients vaccination affected the PSA level suggests that this approach may become useful as a treatment modality for prostate cancer patients.


Subject(s)
Androgens/therapeutic use , Cell Transplantation , Dendritic Cells/immunology , Immunotherapy , Prostatic Neoplasms/therapy , RNA, Messenger/genetics , Transfection , Aged , Cancer Vaccines/adverse effects , Cancer Vaccines/immunology , Cancer Vaccines/therapeutic use , Drug Resistance, Neoplasm , Humans , Hypersensitivity, Delayed , Male , Middle Aged , Prostate-Specific Antigen/blood
12.
Int J Immunopathol Pharmacol ; 17(3): 255-63, 2004.
Article in English | MEDLINE | ID: mdl-15461859

ABSTRACT

Enriched CD34(+) peripheral blood progenitor cells (PBPC) are frequently used as stem cell support in cancer patients following high dose therapy. Since precursor dendritic cells (DCs) originate from haematopoietic progenitor cells, purified CD34(+) cells might also serve as starting cells for ex- vivo production of DC. In the present study we developed a clinical grade procedure for ex- vivo production of DC derived from enriched CD34(+) cells. Different concentrations of CD34(+) cells were grown in gas-permeable Teflon bags with different serum-free and serum-containing media supplemented with GM-CSF, IL-4, TNF-alpha, SCF, Flt-3L and INF-alpha. Serum-free CellGroSCGM medium for 7 days followed by CellGroDC medium in 7 days gave the same results as serum-containing medium. After incubation the cultured cells containing immature DCs were concentrated and transfected with tumour mRNA from human prostate cancer cell lines employing a highly efficient electroporation procedure. Thawed transfected DCs were able to elicit primary T-cell responses in vitro against antigens encoded by the prostate cancer mRNA as shown by ELISPOT assay using mock-transfected DCs as control. Our results show that frozen enriched CD34(+) cells can be an alternative and efficient source for production of DCs for therapeutic purpose.


Subject(s)
Antigens, CD34/metabolism , Dendritic Cells/metabolism , Dendritic Cells/transplantation , RNA, Messenger/biosynthesis , Stem Cells/metabolism , Cell Line, Tumor , Cell Separation , Cryopreservation , Culture Media , Cytokines/metabolism , Growth Substances/metabolism , Humans , Male , Monocytes/metabolism , Monocytes/transplantation , Phenotype , Prostatic Neoplasms , Recombinant Proteins/metabolism , Stem Cell Transplantation , Transfection
13.
Scand J Immunol ; 58(5): 578-86, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14629630

ABSTRACT

With the aim of producing large quantities of mRNA-transfected monocyte-derived dendritic cells (DCs) to be used as cancer vaccines, a new clinical grade procedure has been developed. Peripheral blood mononuclear cells (PBMCs) obtained by leukapheresis were enriched for monocytes by immunomagnetic depletion of CD19+ B cells and CD2+ T cells employing the ISOLEX 300i device. After 5 days of culture of enriched monocytes in gas permeable Teflon bags, using serum-free medium supplemented with granulocyte/macrophage-colony stimulating factor and interleukin-4 (IL-4), immature DCs were generated. Following transfection with mRNA from three human prostate cancer cell lines (DU145, LNCaP and PC-3), employing a newly developed square wave electroporation procedure, the immature DCs were immediately transferred to Teflon bags and matured for 48 h, using serum-free medium supplemented with IL-1alpha, IL-6, tumour necrosis factor-alpha and PGE2. The electroporation procedure efficiently transferred mRNA into the DCs with minor effect on the viability of the cells. The generated matured transfected DCs show high expression of the antigens CD83, CD80, CD86 and human leucocyte antigen-DR. Freezing and thawing of the transfected matured DCs had minor effect on cell viability and the phenotype. From 4 x 109 PBMCs, about 1 x 108 transfected matured DCs are produced. The thawed transfected DCs were able to elicit primary T-cell responses in vitro against antigens encoded by the prostate cancer mRNA as shown by enzyme-linked immunospot assay using mock-transfected DCs as control. Based on these results, clinical trials in cancer patients have been initiated.


Subject(s)
Cancer Vaccines/immunology , Dendritic Cells/immunology , Monocytes/cytology , RNA, Messenger/genetics , Transfection , Adult , Cryopreservation , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunomagnetic Separation , Immunophenotyping , Lymphocyte Depletion , Male , T-Lymphocytes/immunology
14.
Proc Natl Acad Sci U S A ; 98(23): 13255-60, 2001 Nov 06.
Article in English | MEDLINE | ID: mdl-11687624

ABSTRACT

The functional role and specificity of tumor infiltrating lymphocytes (TIL) is generally not well characterized. Prominent lymphocyte infiltration is the hallmark of the most common form of hereditary colon cancer, hereditary nonpolyposis colon cancer (HNPCC) and the corresponding spontaneous colon cancers with the microsatellite instability (MSI) phenotype. These cancers are caused by inherited or acquired defects in the DNA mismatch-repair machinery. The molecular mechanism behind the MSI phenotype provides a clue to understanding the lymphocyte reaction by allowing reliable prediction of potential T cell epitopes created by frameshift mutations in candidate genes carrying nucleotide repeat sequences, such as TGF beta RII and BAX. These tumors therefore represent an interesting human system for studying TIL and characterizing tumor-specific T cells. We here describe T cell reactivity against several T helper cell epitopes, representing a common frameshift mutation in TGF beta RII, in TIL and peripheral blood lymphocytes from patients with MSI(+) tumors. The peptide SLVRLSSCVPVALMSAMTTSSSQ was recognized by T cells from two of three patients with spontaneous MSI(+) colon cancers and from all three patients with HNPCC. Because such mutations are present in 90% of cancers within this patient group, these newly characterized epitopes provide attractive targets for cancer vaccines, including a prophylactic vaccine for individuals carrying a genetic disposition for developing HNPCC.


Subject(s)
Adenocarcinoma/genetics , Antigens, Neoplasm/genetics , Colorectal Neoplasms/genetics , Frameshift Mutation , Peptides/genetics , Proto-Oncogene Proteins c-bcl-2 , Adenocarcinoma/immunology , Amino Acid Sequence , Antigens, Neoplasm/immunology , Base Sequence , Colorectal Neoplasms/immunology , DNA Primers , Female , Humans , Immunohistochemistry , Immunologic Memory , Molecular Sequence Data , Mutation , Peptides/metabolism , Protein Serine-Threonine Kinases , Proto-Oncogene Proteins/chemistry , Proto-Oncogene Proteins/genetics , Receptor, Transforming Growth Factor-beta Type II , Receptors, Transforming Growth Factor beta/chemistry , Receptors, Transforming Growth Factor beta/genetics , T-Lymphocytes/immunology , bcl-2-Associated X Protein
15.
Tumour Biol ; 22(5): 323-7, 2001.
Article in English | MEDLINE | ID: mdl-11553863

ABSTRACT

DNA fragments melt characteristically according to their nucleotide sequence and length, when exposed to denaturants such as temperature, urea or formamide. Small differences within a defined sequence, like a base mutation, will result in a slightly different melting behavior of the aberrant DNA fragment compared to that of the wild type sequence. This feature has previously been exploited for mutation detection by constant denaturant capillary electrophoresis (CDCE). In this report, we describe an automated approach (ACDCE) using a commercially available apparatus (ABI 310 Genetic Analyzer) to analyze mutations in exons 5-8 of TP53. The running conditions were determined by temperature titration of the fragments on the apparatus, and an operating sensitivity showed that 0.1% mutated alleles could be detected against a background of wild-type alleles. Up to 48 samples can be analyzed by ACDCE without any need for operator intervention. The apparatus is commercially available, and there is no need for instrument modification. To our knowledge this is the first report on the analysis of TP53 exons 5-8 by ACDCE.


Subject(s)
Colonic Neoplasms/genetics , Exons , Genes, p53 , Point Mutation , Automation , Base Sequence , Codon , Colonic Neoplasms/pathology , DNA Mutational Analysis , DNA Primers , Electrophoresis, Capillary/methods , Humans , Molecular Sequence Data , Nucleic Acid Denaturation , Polymerase Chain Reaction , Tumor Cells, Cultured
16.
Br J Cancer ; 85(5): 692-6, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11531254

ABSTRACT

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes' C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes' B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer.


Subject(s)
Colorectal Neoplasms/genetics , Databases, Factual , Genes, ras/genetics , Point Mutation , Registries , Adolescent , Adult , Aged , Aged, 80 and over , Codon/genetics , Colorectal Neoplasms/mortality , Disease-Free Survival , Female , Genotype , Humans , Male , Middle Aged , Multivariate Analysis , Mutation, Missense , Neoplasm Staging , Proportional Hazards Models , Survival Analysis , Valine/genetics
17.
Biotechniques ; 30(5): 972-5, 2001 May.
Article in English | MEDLINE | ID: mdl-11355359

ABSTRACT

In this study, we have applied automated constant denaturant capillary electrophoresis (ACDCE) for the detection of KRAS exon 1 mutations. Samples from 191 sporadic colon carcinomas previously analyzed for KRAS mutations with allele-specific PCR (ASPCR), temporal temperature gradient electrophoresis (TTGE), and constant denaturant capillary electrophoresis (CDCE) were analyzed. In ACDCE, an unmodified ABI Prism 310 genetic analyzer with constant denaturant conditions separated fluorescein-labeled PCR products. Temperature in combination with a chemical denaturant was used for separation. The optimal separation conditions for PCR-amplified KRAS exon 1 fragments were determined by adjusting the temperature before electrophoresis. In the ACDCE analysis, the sequence of a mutant was determined by comparing the electropherogram of the fragment to that of known mutations followed by mixing the sample with control mutations before reanalysis. In a titration experiment mixing mutant and wild-type alleles, the sensitivity for mutation detection was shown to be 0.6% in this automated CDCE technique. The automation of CDCE allowed rapid analysis of a large number of test samples over as short period of time and with a commercially available apparatus.


Subject(s)
Autoanalysis , Colorectal Neoplasms/genetics , Electrophoresis, Capillary/methods , Exons , Genes, ras/genetics , Mutation , Codon , Cryopreservation , DNA Mutational Analysis , Hot Temperature , Humans , Polymerase Chain Reaction , Protein Denaturation , Sensitivity and Specificity , Sodium Dodecyl Sulfate , Tumor Cells, Cultured
18.
Exp Dermatol ; 10(3): 161-7, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11380611

ABSTRACT

The rapidly increasing incidence and mortality rate of malignant melanoma, together with the lack of efficient treatment of the late stages, makes it a serious threat to public health. Innovative new treatments are needed. The proteins of the ras-family of proto-oncogenes, functioning as relay switches for signalling pathways between cell surface and nucleus, are involved in cell proliferation, differentiation, apoptosis and transformation. If over-expressed or mutated they can induce and/or maintain a transformed state of a cell. Codon 61 mutations of N-ras seem to be involved in melanoma development on sun exposed sites. In order to induce an immune response towards mutated N-ras proteins we performed a phase 1 feasibility study. Ten melanoma patients were immunized intradermally 6 times with N-ras peptides (residue 49-73) with 4 codon 61 mutations using GM-CSF as adjuvant. HLA typing was not used as an inclusion criterion. Eight patients responded with strong delayed type hypersensitivity reactions. In 2 of the patients an in vitro response to the vaccine could also be detected. The specificity of the reaction could be confirmed by cloning of peptide-specific CD4 positive T cells from peripheral blood of the patients. Intradermal injection of ras peptides using GM-CSF as adjuvant is simple to perform and seems to be efficient in inducing cellular immune responses. Since a majority of the patients showed positive skin reactions and 2 of the patients analysed showed a T-helper response to this melanoma specific antigen, these promiscuous HLA class II binding mutant ras peptides may be candidates for inclusion into vaccine cocktails containing various established CTL epitopes.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage , Melanoma/immunology , Peptide Fragments/administration & dosage , Proto-Oncogene Proteins p21(ras)/administration & dosage , Skin Neoplasms/immunology , Adult , Aged , Antibody Formation , Cell Division/drug effects , Clone Cells/pathology , Feasibility Studies , Female , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Humans , Hypersensitivity, Delayed/immunology , Injections, Intradermal , Male , Melanoma/pathology , Middle Aged , Mutation/immunology , Peptide Fragments/immunology , Proto-Oncogene Proteins p21(ras)/immunology , Skin Neoplasms/pathology , T-Lymphocytes/immunology , Vaccination
19.
Int J Cancer ; 92(3): 441-50, 2001 May 01.
Article in English | MEDLINE | ID: mdl-11291084

ABSTRACT

K-RAS mutations are frequently found in adenocarcinomas of the pancreas, and induction of immunity against mutant ras can therefore be of possible clinical benefit in patients with pancreatic cancer. We present data from a clinical phase I/II trial involving patients with adenocarcinoma of the pancreas vaccinated by i.d. injection of synthetic mutant ras peptides in combination with granulocyte-macrophage colony-stimulating factor. Forty-eight patients (10 surgically resected and 38 with advanced disease) were treated on an outpatient basis. Peptide-specific immunity was induced in 25 of 43 (58%) evaluable patients, indicating that the protocol used is very potent and capable of eliciting immune responses even in patients with end-stage disease. Patients followed-up for longer periods showed evidence of induction of long-lived immunological memory against the ras mutations. CD4(+) T cells reactive with an Arg12 mutation also present in the tumor could be isolated from a tumor biopsy, demonstrating that activated, ras-specific T cells were able to selectively accumulate in the tumor. Vaccination was well tolerated in all patients. Patients with advanced cancer demonstrating an immune response to the peptide vaccine showed prolonged survival from the start of treatment compared to non-responders (median survival 148 days vs. 61 days, respectively; p = 0.0002). Although a limited number of patients were included in our study, the association between prolonged survival and an immune response against the vaccine suggests that a clinical benefit of ras peptide vaccination may be obtained for this group of patients.


Subject(s)
Adenocarcinoma/prevention & control , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Pancreatic Neoplasms/prevention & control , ras Proteins/therapeutic use , Adenocarcinoma/immunology , Adenocarcinoma/mortality , Adjuvants, Immunologic/adverse effects , Adjuvants, Immunologic/therapeutic use , Adult , Aged , Aged, 80 and over , Female , Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects , Humans , Hypersensitivity, Delayed/etiology , Injections, Intradermal , Lymphocytes, Tumor-Infiltrating/immunology , Male , Middle Aged , Pancreatic Neoplasms/immunology , Pancreatic Neoplasms/mortality , Peptides/adverse effects , Peptides/therapeutic use , Survival Rate , T-Lymphocytes/immunology , Treatment Outcome , Vaccination , ras Proteins/adverse effects
20.
Cancer Immunol Immunother ; 50(9): 469-76, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11761441

ABSTRACT

Microsatellite instability (MSI) is recognised as genome-wide alterations in repetitive DNA sequences caused by defects in the DNA mismatch repair machinery. Such mutation patterns have been found in almost all analysed malignancies from patients with hereditary non-polyposis colorectal cancer, and in approximately 15% of sporadic colorectal cancers. In cancers with the MSI phenotype, microsatellite-like sequences in coding regions of various cancer-related genes, including transforming growth factor beta receptor type II (TGF betaRII), are targets for mutations. The TGF betaRII gene harbours a 10-bp polyadenine tract, and mutations within this region are found in 90% of colorectal cancers with MSI. The frameshift mutations result in new amino acid sequences in the C-terminal part of the proteins, prematurely terminating where a novel stop codon appears. In this study we have defined new cytotoxic T lymphocyte (CTL) epitope (RLSSCVPVA), carrying a good HLA-A*0201 binding motif, and resulting from the most common frameshift mutation in TGF betaRII. A CTL line and several CTL clones were generated from an HLA-A2+ normal donor by repeated stimulation of T cells with dendritic cells pulsed with the peptide. One of the CTL clones was able to kill an HLA-A2+ colon cancer cell line harbouring mutant TGF betaRII. This epitope may be a valuable component in cancer vaccines directed at MSI-positive carcinomas.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/immunology , Frameshift Mutation , HLA-A2 Antigen/immunology , Receptors, Transforming Growth Factor beta/genetics , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Antigens, Neoplasm/therapeutic use , Base Sequence , Cancer Vaccines/therapeutic use , Cell Line , Cell Survival , Chromium/metabolism , Dendritic Cells/immunology , Flow Cytometry , Humans , Molecular Sequence Data , Peptides/metabolism , Polymerase Chain Reaction , Protein Serine-Threonine Kinases , Receptor, Transforming Growth Factor-beta Type II , Receptors, Antigen, T-Cell/analysis , Transforming Growth Factor beta/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...